Page 1

Madrigal Pharmaceuticals Madrigal Pharmaceuticals Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 5 , 2021 CONSHOHOCKEN , Pa . , Aug. 05 , 2021 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals , Inc. ( NASDAQ : MDGL ) reports today its second quarter 2021 financial results and provides a summary of corporate accomplishments . Paul Friedman , M.D. , Chief Executive Officer of Madrigal , stated , “ The Madrigal team has made great progress on multiple fronts in the first half of 2021. Importantly , we reached our goal of enrollment to support the 52 week liver biopsy accelerated approval portion of MAESTRO - NASH . Top - line results are expected by the third quarter of 2022 for MAESTRO - NASH and by the end of this year for the non - invasive imaging and biomarker study , MAESTRO - NAFLD - 1 . " " We made multiple presentations recently at EASL . In particular , data from the open - label portion of the ongoing MAESTRO - NAFLD - 1 Phase 3 clinical trial provide further evidence that treatment with resmetirom for 52 weeks leads to rapid and sustained reductions of liver fat , fibrosis , cell injury and inflammation in non - cirrhotic NASH patients that project favorably on the liver biopsy endpoints in MAESTRO - NASH , " stated Becky Taub , M.D. , Chief Medical Officer and President of Research & Development of Madrigal . Dr. Taub added , “ Also during the quarter , the Medical Affairs team at Madrigal continued to engage with the NASH physician and patient advocacy communities that recognize NASH with liver fibrosis as a very large unmet need . Our commercial team's product launch planning also supports our objective to demonstrate the value of available non - invasive imaging and biomarkers that better diagnose and allow management of patients with NASH , enabling preparation for the planned launch and commercialization of resmetirom . " Recent Accomplishments 1. Clinical and Medical Affairs • Positive clinical results presented at the European Association for the Study of the Liver Annual Meeting ( EASL ) , The International Liver CongressTM 2021 , further point out the potential therapeutic value of resmetirom in a real - life NASH setting using non - invasive tools ( versus serial liver biopsies ) : [ click here to view press release ] • Oral Plenary Presentation : Reduction in Fibrosis and Steatohepatitis Imaging and Biomarkers in a Phase 3 , 52 Week Resmetirom NASH Trial . Presenter : Stephen Harrison [ click here to view oral presentation ] • EASL Poster : Treatment of NASH cirrhotic patients with resmetirom : baseline characteristics and effects on safety , biomarkers and imaging . Presenter : Stephen Harrison [ click here to view poster ]